Wire · operational-macro
Dr Reddy's gets tentative US FDA nod for generic HIV prevention
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 November 2026 · Fusion42 review
Dr Reddy's has received tentative US FDA approval for a generic version of the HIV prevention drug lenacapavir, enabling potential sales in 120 low- and middle-income countries, accelerating global access despite US sales restrictions due to patent issues.
This Wire brief sits within Fusion42's coverage of Health: Drug Discovery, and 3 sources have reported it between 2 Nov 2026 and 3 Nov 2026.
◆ ◆ The Wire takeaway
You can enter the HIV prevention drug market in low-income countries now accessible through FDA-backed approvals. This reduces your regulatory burden and opens procurement channels for affordable generic therapies.
◆ Coverage
3 sources · first reported 2 Nov 2026 · latest 3 Nov 2026
◆ Related on Wire
◆ Topics